We are live on ! Find out more
INBX icon

Inhibrx

138 hedge funds and large institutions have $1.01B invested in Inhibrx in 2025 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 38 increasing their positions, 38 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

463% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 8

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

186% more capital invested

Capital invested by funds: $354M → $1.01B (+$658M)

35% more funds holding

Funds holding: 102138 (+36)

23% more call options, than puts

Call options by funds: $54.8M | Put options by funds: $44.6M

15.53% more ownership

Funds ownership: 72.47%88% (+16%)

0% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 38

Holders
138
Holders Change
+36
Holders Change %
+35.29%
% of All Funds
1.68%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
45
Increased
38
Reduced
38
Closed
8
Calls
$54.8M
Puts
$44.6M
Net Calls
+$10.1M
Net Calls Change
+$11.3M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$115M +$8.52M +125,000 +9%
Viking Global Investors
2
Viking Global Investors
Connecticut
$114M -$23.8M -350,000 -20%
Morgan Stanley
3
Morgan Stanley
New York
$92.3M +$49.4M +724,872 +164%
S
4
Sanofi
France
$91.5M
HighTower Advisors
5
HighTower Advisors
Illinois
$68.8M -$85.3K -1,252 -0.1%
BlackRock
6
BlackRock
New York
$61.4M +$6.31M +92,637 +14%
Vanguard Group
7
Vanguard Group
Pennsylvania
$49.2M +$1.92M +28,166 +5%
SI
8
Sofinnova Investments
California
$35.9M +$992K +14,565 +3%
Capital Research Global Investors
9
Capital Research Global Investors
California
$33.3M +$28.7M +421,575 New
State Street
10
State Street
Massachusetts
$29.6M +$11.7M +171,038 +84%
CP
11
Caligan Partners
New York
$25.6M +$5.94M +87,182 +37%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$23.5M +$20.2M +297,116 New
Millennium Management
13
Millennium Management
New York
$21.8M -$1.49M -21,903 -7%
PHS
14
PFM Health Sciences
California
$21M +$1.76M +25,873 +11%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
15
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$20.9M +$18M +264,000 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$17.9M +$279K +4,089 +2%
SSA
17
Schonfeld Strategic Advisors
New York
$17M +$8M +117,343 +120%
WP
18
Woodline Partners
California
$11M -$13.4M -197,111 -59%
Norges Bank
19
Norges Bank
Norway
$10.5M +$9.08M +133,300 New
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$9.65M +$7.53M +110,548 +957%
Invesco
21
Invesco
Georgia
$8.88M +$6.46M +94,822 +540%
CF
22
CDC Financial
Illinois
$8.75M +$7.55M +110,810 New
Goldman Sachs
23
Goldman Sachs
New York
$7.95M +$5.09M +74,651 +287%
BFM
24
Boothbay Fund Management
New York
$7.27M +$899K +13,197 +17%
Northern Trust
25
Northern Trust
Illinois
$6.99M -$283K -4,148 -4%

INBX Hedge Fund Activity: Q4 2025 in Review

138 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q4 2025, worth a combined $1.01B — up 186% from $354M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new INBX positions and 8 closed out — a net gain of 37 holders — while 38 added to existing stakes and 38 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $49.4M. The largest seller was Viking Global Investors, cutting an estimated $23.8M.

  • 138 institutional investors held Inhibrx (INBX) as of Q4 2025, up from 102 in Q3 2025.
  • Funds reported $1.01B of Inhibrx stock for Q4 2025, up 186% quarter-over-quarter.
  • 45 funds opened new Inhibrx positions in Q4 2025 and 8 closed out, a net change of +37 holders.
  • The largest Inhibrx buyer in Q4 2025 was Morgan Stanley, an estimated $49.4M added.
  • The largest Inhibrx seller in Q4 2025 was Viking Global Investors, an estimated $23.8M sold.

Based on aggregated 13F filings for Q4 2025.